Table 3.
Indicators related to the volume and complexity of the activity at the hematology department.
| Outcomes | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | APC (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood cultures per 1000 OBD | 72 | 71 | 59 | 71 | 100 | 121 | 92 | 100 | 100 | 133 | 102 | 6.014 (2.348 to 9.811) |
| AML | 21 | 33 | 35 | 47 | 35 | 37 | 35 | 29 | 43 | 35 | 37 | 4.400 (−6.186 to 16.279) |
| Admissions | 1005 | 1055 | 1081 | 946 | 1052 | 1148 | 1169 | 1120 | 1133 | 1290 | 1265 | 2.336 (1.253 to 3.430) |
| OBD | 8966 | 9128 | 10,616 | 10,463 | 10,343 | 10,620 | 10,840 | 11,135 | 11,753 | 11,719 | 14,463 | 3.540 (2.358 to 4.735) |
| Length of stay, mean | 16 | 15 | 18 | 17 | 17 | 16 | 16 | 16 | 17 | 14 | 16 | −0.843 (−1.908 to 0.235) |
| Allogeneic HSCT | 19 | 20 | 33 | 40 | 47 | 55 | 56 | 58 | 44 | 43 | 47 | 8.609 (4.436 to 12.948) |
| HSCT−related mortality, % | 5.3 | 5.0 | 0 | 0 | 6.4 | 1.8 | 7.1 | 1.7 | 0 | 2.3 | 2.1 | −7.007 (−16.347 to 3.376) |
For each year, data are presented as the number of events, unless otherwise specified. In the last column, the annual percentage of change (APC) obtained from joinpoint regression analysis with a 95% confidence interval (CI) is included. OBD, occupied bed days. AML, acute myeloid leukemia. HSCT-related mortality, hematopoietic stem-cell transplantation (HSCT)-related mortality within the first 100 days after allogeneic HSCT from human leukocyte antigen (HLA)-identical siblings.